Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Xenon Pharmaceuticals (XENE) Tops Q2 EPS by 24c, Revenues Beat
August 6, 2020 5:03 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of $0.00, $0.24 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $13.38 million versus the consensus estimate of $6.9 million.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, Xenon continues to manage well as we respond to the global impacts of the COVID-19 pandemic. We are... More
